{
}
Established vendors like Nokia, Ericsson, and Huawei dominate the private 5G market, but startups such as Celona and Vilicom are gaining traction. Celona has over 100 customers and is being considered by John Deere, while Vilicom recently deployed a 4G LTE network for Bristol-Myers Squibb in Dublin. Other emerging players like Highway 9, with MIT as a key client, are also making their mark in the industry.
UBS analysts have maintained a Neutral rating on Bristol-Myers Squibb (BMY) with a price target of $60, noting the stock is currently trading below its fair value. Despite concerns over Cobenfy's recent prescription stagnation, UBS projects significant sales growth for the product, estimating $18-$21 million in Q1 2025 and $150-$170 million for the year. Additionally, Bristol-Myers has received expanded approvals for its CAR-T therapy and entered an agreement to acquire 2seventy bio for $286 million, reflecting its ongoing commitment to innovation and shareholder value.
UBS has maintained a Neutral rating on Bristol-Myers Squibb, setting a target price of €60, as the company trades below its Fair Value. Despite recent stagnation in Cobenfy prescriptions, analysts project potential sales growth, estimating €18-21 million for Q1 2025 and €150-170 million for the full year. Additionally, Bristol-Myers has received expanded approvals for its CAR-T therapy and entered an agreement to acquire 2seventy bio for €286 million, while continuing to deliver dividends reflecting its financial health.
UBS has maintained a Neutral rating on Bristol-Myers Squibb (BMY) with a price target of $60, noting the stock is currently trading below its fair value. Despite recent stagnation in prescriptions for Cobenfy, analysts project significant sales growth, estimating $18-$21 million for Q1 2025 and $150-$170 million for the full year. Additionally, the European Commission has expanded approvals for Breyanzi and Opdivo-Yervoy, while the company plans to acquire 2seventy bio for $286 million, reflecting its ongoing commitment to innovation and shareholder value.
The High Potency Active Pharmaceutical Ingredients Market is experiencing significant growth, driven by increased demand, technological advancements, and a broadening customer base. A comprehensive report provides insights into market trends, competitive landscape, and future opportunities, highlighting key players such as Lonza and Novartis. The analysis covers various segments, production technologies, and applications, offering a detailed outlook on the industry's trajectory through 2032.
Light Horse Therapeutics has secured $62 million in Series A financing and formed a partnership with Novartis, which includes a $25 million upfront payment and potential milestone payments of up to $1 billion. The biotech aims to revolutionize drug discovery with its genetic editing-based platform, initially focusing on challenging oncology targets while exploring other therapeutic areas in the future.
Light Horse Therapeutics has launched with $62 million in Series A financing led by Versant Ventures, alongside partners including Novartis. The company focuses on developing small molecule therapeutics using a precision gene editing platform to tackle challenging oncology targets, with potential for broader applications. The collaboration with Novartis includes a $25 million upfront payment and up to $1 billion in milestone payments, aiming to create first-in-class therapies.
Light Horse Therapeutics has launched with a $62-million series A financing and a collaboration with Novartis potentially worth over $1 billion. The San Diego-based biotech employs a "function-first" approach to drug discovery, focusing initially on oncology targets while integrating precision genome editing techniques. The partnership includes a $25-million upfront payment and opportunities for significant R&D and sales milestones.
Versant Ventures has launched a new biotech company, Light Horse, securing $62 million in a Series A funding round backed by Bristol Myers Squibb, AbbVie, and others. The company also announced a partnership with Novartis, marking a significant step in its development.
The Congestive Heart Failure market is poised for significant growth, driven by an increase in prevalence and the introduction of innovative therapies like finerenone, tirzepatide, and semaglutide. Key players such as Novartis, Eli Lilly, and Bayer are advancing their drug candidates through clinical development, while off-label therapies and generics continue to dominate the current market landscape. The FDA's recent approvals and label expansions are expected to further enhance treatment options and accessibility for patients.
Bristol-Myers Squibb Co
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
emerging players in the private 5G market challenge established vendors
13:20 02.04.2025
ubs maintains neutral rating on bristol myers with 60 dollar target
15:46 27.03.2025
ubs maintains neutral rating on bristol myers with target price of sixty euro
15:31 27.03.2025
ubs maintains neutral rating on bristol myers with price target of sixty dollars
15:31 27.03.2025
high potency active pharmaceutical ingredients market trends and future growth prospects
Merck & Co., Inc.
Roche Diagnostics AG
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd
BASF AG
Novartis International AG
Lonza Group AG
Bristol-Myers Squibb Co
Cambrex Corporation
Seqens
Pfizer Inc.
Sanofi Aventis SA
Bayer AG
CARBOGEN AMCIS AG
Alice Mutum
Viju Shah
Show more
10:02 26.03.2025
light horse therapeutics secures 62 million and partners with novartis
United States Dollar
Bristol-Myers Squibb Co
Novartis AG
ABBVIE
ARE
USA
John Tallarico
Markus Renschler
Show more
13:38 10.01.2025
light horse therapeutics launched with 62 million funding and novartis partnership
United States Dollar
Bristol-Myers Squibb Co
Novartis AG
ABBVIE
ARE
JPN
USA
Ben Cravatt
Brian Liau
Markus Renschler
John Tallarico
Nathanael Gray
Show more
13:38 10.01.2025
light horse therapeutics secures funding and partnership with novartis
United States Dollar
Bristol-Myers Squibb Co
Novartis AG
ABBVIE
USA
Ben Cravatt
Laure Escoubet
Brian Liau
Markus Renschler
John Tallarico
Nathanael Gray
Show more
16:13 09.01.2025
Versant launches Light Horse with 62 million funding and Novartis partnership
15:32 09.01.2025
congestive heart failure market poised for significant growth by 2034
United States Dollar
Mesoblast Ltd
Eli Lilly and Co
Boehringer Ingelheim KG
Bayer AG
Merck & Co., Inc.
Bristol-Myers Squibb Co
Intra-Cellular Therapies, Inc.
BioCardia, Inc.
Novo Nordisk A/S
scPharmaceuticals Inc.
Lexicon Pharmaceuticals, Inc.
Cytokinetics, Incorporated
Novartis AG
Tenax Therapeutics, Inc.
AstraZeneca PLC
Amgen Inc.
Otsuka Pharmaceutical Co. Ltd.
FRA
DEU
ITA
JPN
GBR
USA
Show more
15:50 07.01.2025
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Industry Mergers & Acquisitions
Finance Mergers & Acquisitions
Domestic Politics
Banking Regulations
Global Financial Events
Retail and Consumer Goods
CEO Changes
Government Policies
Workplace Trends
Elections & Campaigns
Market Analysis and Predictions
Central Bank Actions
Global Trade Developments
Startups & Entrepreneurship
Hedge Funds & Private Equity
Supply Chain Management
Banking & Investment Regulations
Countries:
Companies:
Tesla, Inc.
UniCredit S.p.A.
Banco BPM S.p.A.
Deutsche Bank Money Market PP
JPMorgan Chase & Co.
Barclays PLC
Credit Suisse Strategic Income I
Apple Inc.
CREDIT AGRICOLE
SpaceXCoin USD
Lloyds Banking Group plc
BNP Paribas SA
Amazon.com, Inc.
The Goldman Sachs Group, Inc.
UBS Group AG
Credit Agricole
Banco Santander, S.A.
Reinsurance Group of America, Incorporated
Google Inc.
Amundi S.A.
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Chinese Yuan
Indian Rupee
Japanese Yen
South Korean Won
Offshore Chinese Yuan
Hong Kong Dollar
Norwegian Krone
Filipino Peso
Canadian Dollar
Singapore Dollar
Australian Dollar
Danish Krone
Swedish Krona
Mexican Peso
Qatari Riyal
South African Rand
People: